DYV 800
Alternative Names: DYV-800Latest Information Update: 28 Apr 2023
At a glance
- Originator Dyve Biosciences
- Developer Dyve Biosciences; H. Lee Moffitt Cancer Center and Research Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours